<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165487</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO7708</org_study_id>
    <nct_id>NCT03165487</nct_id>
  </id_info>
  <brief_title>Comparison of the Breast Tumor Microenvironment</brief_title>
  <official_title>Differential Comparison of the Breast Tumor Microenvironment Between Luminal A and Triple Negative Breast Cancer With and Without Radiation Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to identify a molecular signature of tumor stroma from &quot;normal&quot;&#xD;
      adjacent breast tissue obtained prospectively at the time of breast conserving surgery before&#xD;
      and after receiving intraoperative radiation therapy (IORT) in subjects that have luminal A&#xD;
      and triple negative breast cancer. IORT is considered as being standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is evidence that the normal tissue around a tumor plays a role in determining how the&#xD;
      tumor behaves, including how it responds to treatments and how likely it is to recur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with significant mean percent change in Tumor Infiltrating Lymphocytes (TILs)</measure>
    <time_frame>Two weeks</time_frame>
    <description>This outcome measure is designed to measure the amount of TILs in newly diagnosed luminal A and Triple Negative Breast Cancer (TNBC) tumors. The mean percent change in TILS in tumor tissue from initial core biopsy samples will be compared with pathology samples from definitive surgery after IORT between the two different breast cancer sub-types.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Hormone Receptor Positive Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Luminal A Breast Cancer</arm_group_label>
    <description>Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
    <description>triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breast tissue collection</intervention_name>
    <description>During Breast Conservation Surgery, one sample will be collected before and after IORT.</description>
    <arm_group_label>Luminal A Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood will be collected before and after IORT, and at the two week follow-up.</description>
    <arm_group_label>Luminal A Breast Cancer</arm_group_label>
    <arm_group_label>Triple Negative Breast Cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two specimens will be collected. A shaved margin of the area surrounding the tumor,&#xD;
      considered as &quot;normal&quot; tissue, will be collected at two time points. The tissue will be&#xD;
      collected prior to intraoperative radiation therapy, and immediately after. Blood will also&#xD;
      be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the outpatient Breast Surgery and Radiation Oncology&#xD;
        Clinics of Columbia University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, age greater than or equal to 40&#xD;
&#xD;
          -  Core biopsy proven invasive breast carcinoma or DCIS, all subtypes excluding invasive&#xD;
             lobular carcinoma due to increased risk for multifocal disease&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2) negative regardless of hormone&#xD;
             receptor status&#xD;
&#xD;
          -  Clinically less than or equal to 3cm unifocal lesion&#xD;
&#xD;
          -  Clinically node negative&#xD;
&#xD;
          -  Must have diagnostic mammogram performed within last 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) less than or equal to&#xD;
             1&#xD;
&#xD;
          -  Appropriate renal, liver, and hematologic lab values&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifocal disease&#xD;
&#xD;
          -  Clinically N1 disease at diagnosis&#xD;
&#xD;
          -  Invasive lobular carcinoma&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Patients for whom RT would be contraindicated (e.g., connective tissue disorder or&#xD;
             prior ipsilateral breast radiation)&#xD;
&#xD;
          -  Patients with known BRCA1/2 mutations&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eileen Connolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eileen Connolly, MD</last_name>
    <phone>212-305-5050</phone>
    <email>epc2116@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariamne Reyna</last_name>
    <phone>646-317-4244</phone>
    <email>mo2213@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Conolly, MD</last_name>
      <phone>212-305-5050</phone>
      <email>epc2116@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mariamne Reyna</last_name>
      <phone>646-317-4244</phone>
      <email>mo2213@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Eileen Connolly</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>microenvironment</keyword>
  <keyword>IORT</keyword>
  <keyword>Hormone Receptor Positive, HER 2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

